Skip to main content

Table 2 Observation of HER2 conversion in circulating tumor cells

From: Highly sensitive proximity mediated immunoassay reveals HER2 status conversion in the circulating tumor cells of metastatic breast cancer patients

Sample

Primary IHC - HER2

pHER2

tHER2

A01-002

Positive

1.9

5.8

A01-003

 

1.7

5.8

A01-006

 

1.6

5.8

A01-014

 

1.7

7.3

A01-041

 

1.4

7.2

A02-027

 

0.1

ND

A02-034

 

3.9

5.9

A02-035

 

1.2

4.1

A02-036

 

0.1

1.7

A03-019

 

0.9

2.9

A02-039

Negative

1.1

ND

A02-052

 

2.1

7.0

A02-053

 

0.1

3.2

A02-056

 

0.5

ND

A03-008

 

0.7

ND

A01-019

 

1.8

5.9

A01-024

 

1.8

3.2

A01-028

 

3.1

4.0

A01-030

 

ND

ND

A01-034

 

1.7

5.9

A01-042

 

0.3

2.5

A02-001

 

0.7

ND

A02-017

 

2.2

1.1

A02-021

 

2.1

6.9

A02-028

 

6.3

19.4

A02-029

 

3.9

6.0

A02-031

 

4.6

6.6

  1. A total of 27 breast cancer samples analyzed for their HER2 expression and activation are shown in the table. 17 blood samples were obtained from metastatic breast cancer patients with primary HER2-IHC negative status. Up to 59% (10/17) of initial HER2-IHC negative samples showed evidence of HER2 activation (pHER2) in their CTCs (Bold). CTCs with HER2 expression (tHER2) were found in 7 (Bold) out of 17 (41%) blood samples obtained from metastatic breast cancer patients with primary HER2 negative status. Levels of HER2 expression and phosphorylation are shown in CU.